Autres langues CombiGene AB

Actions

Marché Fermé - Nasdaq Stockholm Autres places de cotation 16:59:28 03/05/2024			Varia. 5j.	Varia. 1 janv.
3,73 ^SEK	+1,36 %		-1,06 %	+38,66 %

13/03	Le projet épilepsie CG01 de CombiGene reçoit un brevet dans deux nouveaux pays	CI
21/02	Orphazyme A/S (CPSE:ORPHA) a acquis une participation minoritaire supplémentaire inconnue dans CombiGene AB (publ) (OM:COMBI).	CI

BioStock: CombiGene's pain programme takes important steps forward	03/05
CombiGene AB (publ) publishes annual report for 2023	26/04
Notice of Annual General Meeting in CombiGene AB (publ)	18/04
BioStock: CombiGene's CEO comments on the patent approvals in Australia and India	20/03
CombiGene’s epilepsy project CG01 has been granted patent in two new countries	13/03
CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	13/03
BioStock: Comments from Orphazyme on the investment in CombiGene	04/03
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	21/02
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	21/02
Year-end report January-December 2023 CombiGene AB (Publ)	16/02
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	16/02
BioStock: CombiGene comments on the discontinued CGT2 project	02/02
CombiGene discontinues the preclinical development of the lipodystrophy project CGT2	01/02
CombiGene: "We continue to believe in the epilepsy project CG01"	16/01
CombiGene has regained the global rights to the epilepsy project CG01	13/01
BioStock: CombiGene comments on Eurostars funding	22/12
Eurostars contributes SEK 8,7 million to the financing of the COZY01 pain project	20/12
New issue of CombiGenes, no 5 2023	27/11
BioStock: CombiGene focuses on the pain project	15/11
Interim report January – September 2023 for CombiGene AB (publ)	10/11

Aucun résultat pour cette recherche